Yong Huang

Advent International LP (Advent) is an independent private equity firm founded in 1984 by Henry H. Haight. The firm is headquartered in Boston, Massachusetts.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

The University of Liverpool operates as a university. It offers post graduate research, foundation courses, continuing and professional development, online study, and doctoral college. The company was founded in 1881 and is headquartered in Liverpool, the United Kingdom.

Pappas Capital LLC (Pappas Ventures) is a venture capital firm founded in 1994 by Art M. Pappas. The firm is headquartered in Durham, North Carolina.

Part of W World Corp., Xenon Vision, Inc. is a vision research concern. The company is based in Alachua, FL. Xenon Vision was acquired by Pharmatec, Inc. on November 03, 1992.

Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States.

ABV LLC(Ascent Biomedical) is a venture capital firm founded in 2004 by Steven I Hochberg, Geoffrey W Smith and Steve Hochberg. The firm is headquartered in New York.

Lifeline Technologies, Inc. operates as a health sciences development company which focuses on novel strategies. It offers ChoLESStolife, a non-prescription and non-synthetic cholesterol absorption inhibitor for the reduction of human cholesterol using a fat-free delivery system for soy sterols and stanols. The company was registered by Curtis A. Spilburg and Richard E. Ostlund on October 1, 2002 and is headquartered in Hendersonville, NC.

Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013.

Retrotope, Inc. operates as clinical-stage pharmaceutical company that develops drugs to treat degenerative diseases. It offers drugs and therapies to treat Parkinson’s, Alzheimer’s, mitochondrial myopathies and retinopathies diseases. The company was founded by Charles R. Cantor, Robert J. Molinari, and Mikhail S. Shchepinov in 2006 and is headquartered in Los Altos, CA.

SinuSys Corp. develops medical device therapies to improve the sinus health of patients with chronic sinusitis. Its products include Vent-OS sinus dilation system, Restora steroid-eluting spacer, and SinuSys product pipeline. The company was founded by Jerome Hester and Thomas A. Schreck in 2010 and is headquartered in Palo Alto, CA.

AshHill Investments LLC (AshHill Investments) is a venture capital firm founded in 2011. The firm is headquartered in Ft. Thomas, Kentucky.

Armetheon, Inc. engages in medical development. It specializes in thrombosis and cardiac arrhythmias. The company was founded by Pascal J. Druzgala, Muralitharan Ken Kengatharan and Peter G. Milner in 2011 and is headquartered in Milpitas, CA.

NEURONAX SA develops and provides drugs supporting neural repair to treat degenerative disorders of the central nervous system. Its services include cell culture, in vitro evaluation, neurotrophic and neuroprotective effects analysis, culture analyses, and stem cells. The company was founded by Stéphane Gobron, Fabrice Cailloux, and Pierre-Yves Simonin in 2003 and is headquartered in Saint-Beauzire, France.

Renexxion LLC is a gastrointestinal biopharmaceutical company. It develops naronapride. The company was founded by Peter G. Milner, Muralitharan Kengatharan , and Pascal J. Druzgala in 2014 and is headquartered in Menlo Park, CA.

Sibylla Biotech Srl engages in research and development activities in the pharmaceutical sector. It specializes in studies through its proprietary atom computer simulations for new drug discoveries. The company was founded by Maria Letizia Barreca and Emiliano Biasini in 2017 and is headquartered in Trento, Italy.

Diaccurate SASU engages in the research of diagnostic products. It offers diagnostic products especially in the field of theranostics. The firm operates as a biopharmaceutical company that engages in developing new therapies for the treatment of HIV infection. The company was founded in 2012 and is headquartered in Paris, France.